Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation

Journal of the American College of Cardiology

Volumn 37, Issue 2, 2001, Pages 542-547

  Khan, Ijaz A ^a,b  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CREIGHTON UNIVERSITY CARDIAC CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; FLECAINIDE; PROPAFENONE; QUINIDINE;

ARTICLE; BRADYCARDIA; CARDIOVERSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ATRIAL FIBRILLATION; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; HUMANS; PROPAFENONE; TREATMENT OUTCOME;

EID: 0035137975     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(00)01116-5     Document Type: Article

References (46)

1. Atrial arrhythmias
2. Atrial fibrillation and atrial flutter
3. Atrial fibrillation: Problems in management
4. Atrial fibrillation: A review of mechanism, etiology and therapy
5. Heart rate control in patients with atrial fibrillation
6. Combined use of esmolol and digoxin in the acute treatment of atrial fibrillation and flutter
7. Emergency management of atrial fibrillation and flutter: Intravenous diltiazem versus intravenous digoxin
8. Intravenous digoxin in acute atrial fibrillation results of a randomized, placebo-controlled multicenter trial in 239 patients
9. Restoring sinus rhythm in patients with atrial flutter and fibrillation: Pharmacologic or electrical cardioversion?
10. Short-term effects of atrial fibrillation on atrial contractile function in humans
11. Atrial fibrillation: Restoration and maintenance of sinus rhythm and indications for anticoagulation therapy
12. Rhythm management in atrial fibrillation with a primary emphasis on pharmacological therapy
13. Electrophysiological effects of flecainide and propafenone on atrial fibrillation cycle and relation with arrhythmia termination
14. Acute pharmacologic conversion of atrial fibrillation and flutter: The role of flecainide, propafenone and verapamil
15. The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm
16. Clinical course of recent onset atrial fibrillation treated with oral propafenone
17. Placebo-controlled evaluations of propafenone for atrial tachyarrhythmias
18. Electrophysiologic and antiarrhythmic effects of propafenone: Focus on atrial fibrillation
19. The multiple modes of action of propafenone
20. Propafenone: A promising new antiarrhythmic agent
21. Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease: A randomized, controlled trial
22. Valve of single oral loading dose of propafenone in converting recent onset atrial fibrillation: Results of a randomized, double-blind, controlled study
23. Conversion of recent onset atrial fibrillation to sinus rhythm using a single loading oral dose of propafenone: Comparison of two regimens
24. Predictors of success in the conversion of new-onset atrial fibrillation using oral propafenone
25. Oral loading with propafenone: A placebo-controlled study in elderly and nonelderly patients with recent onset atrial fibrillaton
26. Conversion of recent onset atrial fibrillation with single loading oral dose of propafenone: Is in-hospital admission absolutely necessary?
27. Propafenone for conversion of recent-onset atrial fibrillation: A controlled comparison between oral loading dose and intravenous administration
28. A randomized, crossover, controlled comparison of oral loading versus intravenous infusion of propafenone in recent-onset atrial fibrillation
29. Conversion of recent onset atrial fibrillation to sinus rhythm: Effect of different drug protocols
30. Propafenone for the treatment of supraventricular tachycardia and atrial fibrillation: A meta-analysis
31. Conversion of recent onset atrial fibrillation by a single oral loading dose of propafenone or flecainide
32. Regular ventricular rhythms before conversion of recent onset atrial fibrillation to sinus rhythm
33. A controlled study on oral propafenone versus digoxin plus quinidine in converting recent-onset atrial fibrillation to sinus rhythm
34. Comparison of oral loading dose of propafenone and amiodarone for converting recent-onset atrial fibrillation
35. Safety of oral propafenone in the conversion of recent-onset atrial fibrillation to sinus rhythm: A prospective parallel placebo-controlled multicenter study
36. Oral propafenone for rapid conversion of recent-onset atrial fibrillation
37. Clinical pharmacokinetics of propafenone
38. In vitro protein binding of propafenone and 5-hydroxypropafenone in serum, in solutions of isolated serum proteins and to red blood cells
39. Polymorphism of propafenone metabolism and disposition in man: Clinical and pharmacokinetic consequences
40. Potent electrophysiologic effects of the major metabolites of propafenone in canine Purkinji fibers
41. Minimal effective concentration values of propafenone and 5-hydroxypropafenone in acute and chronic therapy
42. Propafenone in the conversion of atrial fibrillation in patients suffering from chronic renal failure
43. Severe reactive airway disease induced by propafenone
44. Congestive heart failure induced by six of the newer antiarhythmic drugs
45. Evaluation of the asthmogenicity of propafenone, a new antiarrhythmic drug: Comparison of spirometry with methacholine challenge
46. Effect of flecainide and propafenone on systolic performance in subjects with normal cardiac function